Hytrin 2

Terazosin, the active ingredient in Hytrin 2, is an alpha‑1 adrenergic blocker presented as a tablet for oral use. It is used to lower high blood pressure and to relieve urinary obstruction caused by an enlarged prostate in adult patients.

GNH USA supplies Hytrin 2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, traceability and on‑time delivery across continents.

Terazosin is indicated for conditions that involve alpha‑1 mediated vascular tone and smooth‑muscle contraction.

- Hypertension: reduces peripheral vascular resistance, helping to control elevated blood pressure. - Benign prostatic hyperplasia: relaxes prostatic and bladder neck smooth muscle, improving urinary flow.

Terazosin may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion or runny nose. - Nausea. - Flushing. - Peripheral edema.

Serious or Rare Side Effects: - Severe hypotension leading to fainting. - Priapism (prolonged painful erection). - Allergic reactions such as rash, swelling, or anaphylaxis. - Rare liver injury manifested by jaundice or elevated enzymes.

Before prescribing terazosin, clinicians should evaluate several safety considerations.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Cardiovascular status: use caution in patients with recent myocardial infarction or unstable angina. - Liver or kidney impairment: dose may need adjustment; monitor hepatic and renal function. - Concomitant alpha‑blockers: avoid combined use due to additive hypotensive effect. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Terazosin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other alpha‑blockers (e.g., prazosin, doxazosin): may cause severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase terazosin plasma levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension; monitor blood pressure. - Antihypertensives (e.g., ACE inhibitors, ARBs): additive blood pressure lowering; adjust doses as needed. - Sildenafil or other PDE5 inhibitors: can cause pronounced hypotension; observe patient closely.